Wall Street Zen Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy

Key Points

• Wall Street Zen upgraded ADMA Biologics to a "buy", joining other bullish moves (Canaccord initiated coverage with a $21 target and Zacks raised its rating); analysts' consensus is a Buy with an average price target of $25.67.
• ADMA reported quarterly EPS of $0.20 (in line with estimates) and revenue of $139.16M (up 18.4% YoY); the stock recently opened at $11.26, trades in a 12‑month range of $7.21–$25.67, and has a market cap of about $2.68B with a P/E of 18.77.
• Insider activity was mixed—Director Steve Elms bought 7,000 shares while the COO sold ~10,096 shares—and institutional/hedge funds own roughly 75.7% of the company, indicating strong institutional interest.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Sunday.

A number of other analysts have also issued reports on ADMA. Canaccord Genuity Group began coverage on ADMA Biologics in a research note on Monday, April 20th. They issued a "buy" rating and a $21.00 price target on the stock. Zacks Research raised ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Mizuho reduced their price objective on ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating on the stock in a research note on Monday, April 13th. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics has an average rating of "Buy" and a consensus price target of $25.67.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $11.26 on Friday. The stock has a 50 day moving average of $12.94 and a two-hundred day moving average of $15.68. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $25.67. The stock has a market cap of $2.68 billion, a P/E ratio of 18.77 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same period last year, the company earned $0.46 EPS. The firm's quarterly revenue was up 18.4% on a year-over-year basis. On average, research analysts forecast that ADMA Biologics will post 0.93 earnings per share for the current year.

Insider Activity

In related news, Director Steve Elms bought 7,000 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the acquisition, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm's stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently modified their holdings of the stock. Lido Advisors LLC raised its holdings in shares of ADMA Biologics by 3.8% during the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company's stock valued at $312,000 after buying an additional 629 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of ADMA Biologics by 11.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company's stock valued at $117,000 after buying an additional 634 shares during the period. Cim LLC increased its holdings in ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock worth $1,341,000 after purchasing an additional 665 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 700 shares during the last quarter. Finally, Clearstead Advisors LLC increased its holdings in ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 795 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.